Dymista™

DRUG2 trials

Sponsors

Teva Pharmaceuticals USA, Synmosa Biopharma Corp.

Conditions

Allergic RhinitisSeasonal Allergic Rhinitis

Phase 2

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis

CompletedNCT06051786

Synmosa Biopharma Corp.Allergic Rhinitis

Start: 2020-08-20End: 2021-07-20Updated: 2023-09-25

Phase 3

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

Teva Pharmaceuticals USASeasonal Allergic Rhinitis

Start: 2014-08-31Target: 1535Updated: 2014-09-25